Nowhere in that statement does he say anything about raising funds by methods that help the share PRICE, he says "through methods that best serve the company and its shareHOLDERS". If the choice is dilute or run out of money, then selling shares is in the best interest of the shareholders. I'm also a little concerned that he said "we have cash on hand to advance clinical priorities in 2025" because our 2025 fiscal year ended May 31st and we are now in fiscal year 2026.
This new and improved communication style still leaves a lot to be desired. I was hoping for a quarterly shareholder letter early this week, which would have been in line with the timing they've been keeping on the last few but if we don't get one tomorrow, with Thursday being a holiday, we probably won't get something until next week. The new ESMO abstract should be available next week at least.